Evidence map›Paper›PMID 42403505›Full record

ArticleTherapeutic advances in medical oncology2026

Clinical significance of high-density lipoprotein cholesterol and its dynamic change in patients with lymphoma-associated hemophagocytic lymphohistiocytosis.

Jing Zhang, Jie Zhang, Shanza Ahmed, Yilian Yang, Yanping Liu, Xuzhang Lu, Meng Wu, Bingzong Li, Chunling Wang, Liang Yu and 26 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Jing ZhangDepartment of Hematology, Lymphoma Center, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.ORCID https://orcid.org/0000-0002-5302-9873
Jie ZhangDepartment of Oncology, The Affiliated Hospital of Nantong University, Nantong, China.
Shanza AhmedDepartment of Oncology, The Affiliated Hospital of Nantong University, Nantong, China.
Yilian YangDepartment of Hematology, Lymphoma Center, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Yanping LiuDepartment of Hematology, Lymphoma Center, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Xuzhang LuDepartment of Hematology, The Affiliated Changzhou Second Hospital of Nanjing Medical University, Changzhou, China.
Meng WuDepartment of Oncology, The Affiliated Hospital of Nantong University, Nantong, China.
Bingzong LiDepartment of Hematology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Chunling WangDepartment of Hematology, The First People's Hospital of Huai'an, Huai'an, China.
Liang YuDepartment of Hematology, The First People's Hospital of Huai'an, Huai'an, China.
Miao SunDepartment of Hematology, Jingjiang People's Hospital, The Seventh Affiliated Hospital of Yangzhou University, Jingjiang, China.
Yun ZhuangDepartment of Hematology, Wuxi People's Hospital, Wuxi, China.
Yuqing MiaoDepartment of Hematology, Yancheng First People's Hospital, Yancheng, China.
Haiwen NiDepartment of Hematology, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Xiaoyan XieDepartment of Hematology, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, China.
Jingyan XuDepartment of Hematology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
Yunping ZhangDepartment of Hematology, The Affiliated Yixing Hospital of Jiangsu University, Yixing, China.
Min ZhaoDepartment of Hematology, Wuhu Second People's Hospital, Wuhu, China.
Min XuDepartment of Hematology, Zhangjiagang First Affiliated Hospital of Soochow University, Zhangjiagang, China.
Wanchuan ZhuangDepartment of Hematology, The Second People's Hospital of Lianyungang, Lianyungang, China.
Weiying GuDepartment of Hematology, The First People's Hospital of Changzhou and The Third Affiliated Hospital of Soochow University, Changzhou, China.
Guoqiang LinDepartment of Hematology, Huai'an Hospital Affiliated to Xuzhou Medical College and Huai'an Second People's Hospital, Huai'an, China.
Haiying HuaDepartment of Hematology, The Affiliated Hospital of Jiangnan University, Wuxi, China.
Jianfeng ZhuDepartment of Hematology, The People's Hospital of Taizhou, Taizhou, China.
Maozhong XuDepartment of Hematology, The Affiliated Jiangyin Hospital of Southeast University Medical College, Jiangyin, China.
Tao JiaDepartment of Hematology, The First People's Hospital of Lianyungang, Lianyungang, China.
Ping LiuDepartment of Hematology, Wuxi Second People's Hospital, Wuxi, China.
Lijia ZhaiDepartment of Hematology, The Affiliated Hospital of Yangzhou University, Yangzhou, China.
Tongtong ZhangDepartment of Hematology, Rudong County People's Hospital, Rudong, China.
Huirong ShanDepartment of Hematology, Shuyang Hospital of Traditional Chinese Medicine, Shuyang, China.
Qiudan ShenDepartment of Hematology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, China.
Jun QianDepartment of Hematology, The Affiliated People's Hospital of Jiangsu University, Zhenjiang, China.
Lei FanDepartment of Hematology, Lymphoma Center, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Jianyong LiDepartment of Hematology, Lymphoma Center, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu 210029, China.
Wenyu ShiDepartment of Hematology, The Affiliated Hospital of Nantong University, 20 Xisi Road, Nantong, Jiangsu 226001, China.ORCID https://orcid.org/0000-0002-2371-3332
Yi MiaoDepartment of Hematology, Lymphoma Center, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu 210029, China.ORCID https://orcid.org/0000-0003-1799-1448

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hemophagocytic lymphohistiocytosis (HLH) is a fatal disorder characterized by uncontrolled inflammation. In adults, lymphoma is the most common underlying cause. The lipid profile is frequently dysregulated in lymphoma-associated HLH (LA-HLH), and the clinical significance remains to be determined. Objectives: This study aimed to evaluate the prognostic value of baseline lipid profiles and the dynamic changes in high-density lipoprotein cholesterol (HDL-c) in adult patients with LA-HLH. Design: A multicenter, retrospective cohort study. Methods: We analyzed 277 adult patients with LA-HLH from 27 medical centers (2015-2023). Baseline lipid levels and post-treatment HDL-c levels were measured. The optimal prognostic cutoff was determined using X-tile software. Survival analysis was performed using Kaplan-Meier and Cox regression methods. Results: Low HDL-c (<1.03 mmol/L) was observed in 93.9% (260/277) patients at diagnosis. A baseline HDL-c <0.48 mmol/L was independently associated with reduced overall survival (OS; hazard ratio, HR = 1.51, 95% confidence interval, CI: 1.10-2.09, Conclusion: HDL-c and its dynamic changes are clinically feasible markers for predicting outcomes in patients with LA-HLH.

Indexed as

hemophagocytic lymphohistiocytosislipoprotein cholesterollymphomaoutcomesurvival

Identifiers

PMID42403505
PMCPMC13332294

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.